Verrica Pharmaceuticals (VRCA) Competitors $4.39 +0.35 (+8.66%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.22 -0.17 (-3.87%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. NLTX, ENTA, BIOA, IVVD, TVGN, KYTX, CABA, CRBU, BTMD, and MISTShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), BioAge Labs (BIOA), Invivyd (IVVD), Tevogen Bio (TVGN), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Caribou Biosciences (CRBU), biote (BTMD), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Neoleukin Therapeutics Enanta Pharmaceuticals BioAge Labs Invivyd Tevogen Bio Kyverna Therapeutics Cabaletta Bio Caribou Biosciences biote Milestone Pharmaceuticals Neoleukin Therapeutics (NASDAQ:NLTX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Which has higher valuation & earnings, NLTX or VRCA? Neoleukin Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.53Verrica Pharmaceuticals$14.70M2.82-$76.58M-$8.28-0.53 Is NLTX or VRCA more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Verrica Pharmaceuticals N/A N/A -115.48% Do insiders & institutionals have more ownership in NLTX or VRCA? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, NLTX or VRCA? Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Does the media favor NLTX or VRCA? In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.64 beat Neoleukin Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Verrica Pharmaceuticals Positive Do analysts recommend NLTX or VRCA? Verrica Pharmaceuticals has a consensus target price of $80.00, suggesting a potential upside of 1,722.32%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryVerrica Pharmaceuticals beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.47M$2.55B$5.80B$10.44BDividend YieldN/A55.04%5.61%4.57%P/E Ratio-0.5323.0180.5826.84Price / Sales2.82539.41516.24162.98Price / CashN/A27.8326.0131.15Price / Book-4.105.2915.556.42Net Income-$76.58M$32.95M$3.30B$271.73M7 Day Performance-11.13%1.99%3.91%2.82%1 Month Performance-19.74%2.97%5.24%6.60%1 Year Performance-75.75%-2.98%78.04%28.60% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.0509 of 5 stars$4.39+8.7%$80.00+1,722.3%-75.7%$41.47M$14.70M-0.5340Gap UpHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.00-5.4%N/A-57.8%$178.56MN/A-6.1190High Trading VolumeENTAEnanta Pharmaceuticals4.0265 of 5 stars$7.46-9.9%$20.20+170.8%-32.3%$177.01M$67.64M-1.73160High Trading VolumeBIOABioAge Labs0.0333 of 5 stars$4.80flatN/AN/A$172.08MN/A0.00N/AHigh Trading VolumeIVVDInvivyd3.4346 of 5 stars$1.28-10.5%$3.18+148.7%+1.7%$171.80M$25.38M-1.39100TVGNTevogen Bio2.463 of 5 stars$0.84-2.7%$10.00+1,087.5%+64.9%$170.29MN/A-4.433KYTXKyverna Therapeutics2.5092 of 5 stars$3.91-0.3%$16.60+324.6%-9.2%$169.52M$7.03M-1.0696Gap UpCABACabaletta Bio3.0815 of 5 stars$1.91+3.8%$14.50+659.2%-53.4%$168.30MN/A-0.7050Positive NewsCRBUCaribou Biosciences2.5584 of 5 stars$1.83+1.7%$6.67+264.3%-18.4%$167.62M$9.99M-1.03100Positive NewsBTMDbiote2.8568 of 5 stars$3.45+2.4%$6.00+73.9%-47.6%$166.61M$197.19M3.83194Positive NewsMISTMilestone Pharmaceuticals1.8716 of 5 stars$1.97+0.5%$4.50+128.4%+23.9%$166.59M$1M-2.3530 Related Companies and Tools Related Companies NLTX Alternatives ENTA Alternatives BIOA Alternatives IVVD Alternatives TVGN Alternatives KYTX Alternatives CABA Alternatives CRBU Alternatives BTMD Alternatives MIST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredThis soon could be the most precious company in AmericaAI is devouring power at an unprecedented rate. Google alone expects its annual electricity bill to jump by $2...True Market Insiders | SponsoredAI calendar predicts next stock market surgeMost investors are guessing which AI stock could soar next. But one former hedge fund manager mapped out the e...Brownstone Research | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRCA Stock Alerts